26th week of 2021 patent applcation highlights part 25 |
Patent application number | Title | Published |
20210198232 | COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME - A compound of Chemical Formula 1, and an organic light emitting device including the same. | 2021-07-01 |
20210198233 | Thiophene derivatives - Compounds of the formula I | 2021-07-01 |
20210198234 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME - Provided are solid forms of a compound useful for treating cancer, pharmaceutical compositions thereof, and methods of treating cancer comprising administering the solid forms described herein to a patient in need thereof. | 2021-07-01 |
20210198235 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF - The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer. | 2021-07-01 |
20210198236 | CRYSTALS OF CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF - A crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having peaks at diffraction angles 2θ (°) of 12.6±0.2, 16.0±0.2, 17.7±0.2, 18.5±0.2, and 21.3±0.2 in powder X-ray diffraction; and the crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having an endothermic peak at 173° C. to 177° C. in simultaneous thermogravimetric-differential thermal analysis. | 2021-07-01 |
20210198237 | PIPERIDINES AS MENIN INHIBITORS - The present disclosure provides compounds represented by Formula I: | 2021-07-01 |
20210198238 | IRE1 KINASE INHIBITORS AND USES THEREOF - Disclosed herein are, inter alia, compounds modulating Inositol-Requiring Enzyme 1α (IRE1α) and IRE1β activity and methods of use thereof for treating IRE1α-mediated and IRE1β-mediated disorders. | 2021-07-01 |
20210198239 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR - Disclosed are compounds of Formula I: | 2021-07-01 |
20210198240 | HETEROCYCLIC COMPOUND AND USE THEREOF - The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. | 2021-07-01 |
20210198241 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS - Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain. | 2021-07-01 |
20210198242 | BIHETEROCYCLIC COMPOUND - The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter | 2021-07-01 |
20210198243 | POLYMERS FOR USE IN ELECTRONIC DEVICES - Disclosed is a polyanhydride having Formula I | 2021-07-01 |
20210198244 | SMALL MOLECULE ACTIVATORS OF MITOCHONDRIAL FUNCTION - Methods for improving mitochondrial function, decreasing iron accumulation, and/or decreasing oxidative stress by exposing cells or treating a subject to compounds or compositions of the general formula | 2021-07-01 |
20210198245 | EMOPAMIL BINDING PROTEIN BINDING AGENT AND USE THEREOF - Required are: a compound having high affinity for an emopamil binding protein; and a method for activating or inhibiting the emopamil binding protein, using such a compound. According to the present invention, provided is an emopamil binding protein binding agent comprising an alkyl ether derivative represented by the following formula [1] or a salt thereof: | 2021-07-01 |
20210198246 | APELIN RECEPTOR AGONISTS AND METHODS OF USE - The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments. | 2021-07-01 |
20210198247 | Indoleamine-2,3-dioxygenase inhibitor, the preparative method and the use thereof - Provided is a compound represented by formula (I). Also provided are a pharmaceutical composition containing the compound of formula (I) and use of the compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for preparing drugs for preventing and/or treating diseases having pathological features of IDO-mediated tryptophan metabolic pathways. | 2021-07-01 |
20210198248 | FUMARATE SALT OF 5-((5-METHYL-2-((3,4,5-TRIMETHYLPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-BENZO[- D]OXAZOL-2(3H)-ONE - A fumarate salt, in particular the hemi-fumarate salt, of 5-((5-methyl-2-((3,4,5-trimethylphenyl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3H)-one (Compound (I), compositions comprising such a salt, and processes for the manufacture of such a salt, in particular Compound (I) hemi-fumarate salt are described. The salt is useful for the treatment of conditions such as asthma and COPD, involving modulation of the JAK pathway or inhibition of JAK kinases particularly JAK1. | 2021-07-01 |
20210198249 | INDANES AS NRF2 ACTIVATORS - The present invention relates to indane compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I) or Formula (II), and pharmaceutically acceptable salts thereof: | 2021-07-01 |
20210198250 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES - The invention relates to succinic acid addition salts or fumaric acid addition salts of piperazine derivatives of formula (I), as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glucosidase inhibitors. | 2021-07-01 |
20210198251 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT - The present invention comprises compounds of Formula I. | 2021-07-01 |
20210198252 | SMYD INHIBITORS - The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such a SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. | 2021-07-01 |
20210198253 | CRYSTAL FORM OF 1H-IMIDAZO[4,5-B]PYRIDINE-2(3H)-ONE COMPOUND AND PREPARATION PROCESS THEREFOR - Disclosed are a crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and a preparation process therefor, and use of the crystal form in the manufacture of a medicament for treating a disease associated with PDE4 receptor. | 2021-07-01 |
20210198254 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION - Described herein are compounds and compositions, and methods of making and their use as effective agents against mycobacterial infections. | 2021-07-01 |
20210198255 | HETEROCYCLIC COMPOUNDS, PREPARATION AND METHODS AND USES THEREOF - Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer). | 2021-07-01 |
20210198256 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 - Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1. | 2021-07-01 |
20210198257 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS - Compounds of the formula (I), in which R1, R3, Het | 2021-07-01 |
20210198258 | INTEGRIN ANTAGONISTS - The present invention relates to novel integrin antagonists of Formula (I) and their use as a medicament, in particular for inhibiting neovascularization. | 2021-07-01 |
20210198259 | HETEROCYCLIC DERIVATIVES AND USE THEREOF - The present invention relates to novel heterocyclic compounds useful in preparing drugs for the treatment of diseases associated with various functions of the histamine 4 receptor. Specifically, these drugs are useful in the prevention or treatment of inflammatory disorder, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itch skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, age-related macular degeneration, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type I) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer. | 2021-07-01 |
20210198260 | NOVEL PHOSPHOR-TETRAZINE COMPOUND AND USE THEREOF - The present invention relates to a novel phosphor-tetrazine and a use thereof and, more particularly, provides a novel compound having high fluorescence amplification efficiency in various wavelength ranges by using a compound having a novel core skeleton called tert-butyl (3-(7-(6-methyl-1,2,4,5-tetrazin-3 -yl)-3-oxo-9-phenyl-1H-pyrrolo[3,4-b]indolizin-2(3H)-yl)propyl)carbamate. | 2021-07-01 |
20210198261 | AURORA KINASE INHIBITORS AND USES THEREOF - The invention relates to a type of novel pyridine compound and a preparation method and application thereof. Specifically, the invention relates to a compound of formula (1) and a preparation method thereof, and an application of the compound of formula (1) and pharmaceutically acceptable salts thereof as aurora kinase inhibitors in preparation of anti-tumor drugs. | 2021-07-01 |
20210198262 | METHOD OF PREPARATION OF FLORASULAM - The present disclosure concerns a method for preparing florasulam which involves treating a solution of 2,6-difluoroaniline in 1,2-propylene glycol with: a) sulfonyl chloride III and then b) a base to provide, after workup and isolation, florasulam (I) in yields of about 65-85%. The treatment of 2,6-difluoroaniline with sulfonyl chloride III and the base are conducted by controlled additions. | 2021-07-01 |
20210198263 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS - The present disclosure relates to compounds of formula (I′) and pharmaceutically acceptable salts thereof useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions thereof, and methods of use thereof. Compounds as disclosed herein can be useful in the treatment of a disease or disorder involving mitochondrial dysfunction, including neurodegenerative diseases. | 2021-07-01 |
20210198264 | SOLID FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]- PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-EN- ENITRILE - Solid forms of Compound (I): | 2021-07-01 |
20210198265 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE - A temozolomide compound according to formula (I) | 2021-07-01 |
20210198266 | METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES - The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) “back of the eye” retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g. retinal vein occlusion, retinal artery occlusion), and retinal degenerations and dystrophies, in a subject. Particularly, the disclosed compounds exhibit improvements over STO-609, a well characterized specific inhibitor of CaMKK2. The disclosed compounds exhibit enhanced aqueous solubility and formulation, as well as elimination of non-binding isomers during production. The disclosed inhibitor compounds can be used to effectively treat ophthalmic diseases, cancers, appetite disorders, systemic inflammatory diseases, and the like. | 2021-07-01 |
20210198267 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST - Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist. | 2021-07-01 |
20210198268 | PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 2021-07-01 |
20210198269 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) - The present invention relates to 2,6-methanobenzo[g][l]oxacin-4-onecompounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][l]oxacin-4-one compounds and their analog compounds. | 2021-07-01 |
20210198270 | PHENYLBENZOFURAN COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING THE SAME AND MEDICAL APPLICATION THEREOF - The invention discloses a phenylbenzofuran compound, preparation method therefor, composition containing the same and medical application thereof. The phenylbenzofuran compound is represented by the formula | 2021-07-01 |
20210198271 | LIPHAGAL ANALOG AND MULTI-TARGETED KINASE INHIBITOR CONTAINING LIPHAGAL OR ANALOG THEREOF - Provided is an inhibitor for at least one kind of kinase selected from the group consisting of CDK7, CDK4, CDK6, PIM2, TSSK3, MST4, NEK6, MAP3K, MST3, DDR1, SPHK1, CaMK1, AurA, BRK, CaMK4, and PIM1, the inhibitor including as an active ingredient a compound represented by the following general formula (1) or a salt thereof: in the general formula (1), R | 2021-07-01 |
20210198272 | DEEP-SEA FUNGUS-DERIVED ANTHRAQUINONE COMPOUND AND USE THEREOF IN PREPARING ANTI-ALLERGIC DRUGS - An anthraquinone compound and the use thereof in preparing anti-allergic drugs. The anthraquinone compound has a structure according to formula (I) and can be used to prepare anti-allergic drugs. | 2021-07-01 |
20210198273 | GAMMA-SPIROKETAL-GAMMA-LACTONES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PROCESS FOR PREPARATION THEREOF - The present invention relates to γ-spiroketal-γ-lactones of formula (I) or a stereoisomer, ester, hydrate, solvate or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient and a process for preparation thereof. The present invention further provides a pharmaceutical composition comprising γ-spiroketal-γ-lactones of formula (I) or a salt thereof. | 2021-07-01 |
20210198274 | Crystal Form Of Tenvermectin B, Preparation Method Therefor, And Use Thereof - The present invention relates to a crystal form I of tenvermectin B, which can be characterized by X-ray powder diffraction (XRPD) pattern, Infrared (IR) absorption spectrum, Differential scanning calorimetry (DSC) thermogram and the like. Meanwhile, the present invention also relates to a method for preparing the crystal form I of tenvermectin B and a use thereof. | 2021-07-01 |
20210198275 | SALT OF FUSED RING PYRIMIDINE COMPOUND, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a salt of a fused ring pyrimidine compound, a crystal form thereof and a preparation method therefor and the use thereof. The fused ring pyrimidine compound is N-[7-(4-fluoro-2-methoxyphenyl)-6-methylthieno[3,2-d]pyrimidin-2-yl]-1-(piperidin-4-yl)-1H-pyrazol-4-amine, having a structure as shown in formula 1. The preparation methods in the invention for the salt of the fused ring pyrimidine compound and the crystal form thereof are simple; and the salt of the fused ring pyrimidine compound and the crystal form thereof at least have the characteristics of having a better stability, not easily absorbing moisture, being of a polycrystalline type, having a chemical stability and pharmacokinetics, and having an improved solubility. | 2021-07-01 |
20210198276 | FORMS AND COMPOSITIONS OF A MK2 INHIBITOR - The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same. | 2021-07-01 |
20210198277 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS - The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes. | 2021-07-01 |
20210198278 | SECO MACROLIDE COMPOUNDS - The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents. | 2021-07-01 |
20210198279 | ANTIBACTERIAL AGENTS: DUAL-TARGETED RNA POLYMERASE INHIBITORS - The invention provides bipartite, dual-targeted inhibitors of bacterial RNA polymerase having the general structural formula (I): X-α-Y (I) wherein X is an moiety that binds to the Rif target of a bacterial RNA polymerase; Y is a moiety that binds to the bridge-helix N-terminus target of a bacterial RNA polymerase; and is a covalent bond or a linker. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy. | 2021-07-01 |
20210198280 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY - This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The description also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2021-07-01 |
20210198281 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS - The present invention relates to compounds of Formula I | 2021-07-01 |
20210198282 | SALTS OF COMPOUNDS AND CRYSTALS THEREOF - The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38, 40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34λ | 2021-07-01 |
20210198283 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE - The present invention relates to the compound of formula (Ia) wherein a-d and p are 1 or 2, R | 2021-07-01 |
20210198284 | GOLD COMPOSITIONS AND METHODS OF USE THEREOF - Gold compounds and pharmaceutically acceptable salts thereof are disclosed. Certain compounds and salts are active as antibacterial, antifungal, and/or anti-parasitic agents. The disclosure provides pharmaceutical compositions containing the gold compounds. Methods of using the gold compounds to treat bacterial infections are disclosed. | 2021-07-01 |
20210198285 | Method for Producing an Organic Electronic Component, and Organic Electronic Component - A metal complex is disclosed. In an embodiment a metal complex includes at least one metal atom M and at least one ligand L attached to the metal atom M, wherein the ligand L has the following structure: | 2021-07-01 |
20210198286 | Method of preparing metal complexes of formula Z-M, in particular carbene-metal complexes - The present invention relates to an improved method of preparing metal complexes, in particular carbene-metal complexes. The method comprises the step of subjecting a salt of formula Z | 2021-07-01 |
20210198287 | METALLOPORPHYRIN COMPOUNDS, PREPARATION AND USES THEREOF - This disclosure relates to pharmaceutical chemistry, and more particularly to a metalloporphyrin compound, and a preparation and application thereof. The metalloporphyrin compound is shown in formula (I), or an optical isomer, a pharmaceutically-acceptable salt or a solvate thereof, and can specifically recognize the HIV RNA and effectively inhibit HIV reverse transcriptase. This disclosure also provides uses of the compound in the preparation of a reagent for selectively recognizing HIV TAR RNA and a HIV reverse transcriptase inhibitor. | 2021-07-01 |
20210198288 | PENICILLIN-BINDING PROTEIN INHIBITORS - Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections. | 2021-07-01 |
20210198289 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2021-07-01 |
20210198290 | CYCLIC SILOXANES, COMPOSITIONS, METHODS, AND ARTICLES - A cyclic siloxane compound, composition, method, and an article including the siloxane, wherein the cyclic siloxane has the following Formula (I): wherein: each R | 2021-07-01 |
20210198291 | HYDROSILYLAMINES AND FLUOROSILYLAMINES AND METHODS OF MAKING THE SAME - The present disclosure is directed to hydrosilyl amines and fluorosilyl amines and methods of making the same. | 2021-07-01 |
20210198292 | METAL TIN CYCLIZED PERYLENE DIIMIDE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND METHOD FOR USING THE SAME - A metal tin cyclized perylene diimide derivative, having a structure formula of: | 2021-07-01 |
20210198293 | MONOALKYL TIN COMPOUNDS WITH LOW POLYALKYL CONTAMINATION, THEIR COMPOSITIONS AND METHODS - A pure composition comprises a monoalkyltin trialkoxide compound represented by the chemical formula RSn(OR′) | 2021-07-01 |
20210198294 | Novel Lipids - The present invention includes compound having the following structural formula: | 2021-07-01 |
20210198295 | TRIPHOSPHONATE COMPOSITIONS, SELF-ASSEMBLED TRIPHOSPHONATE MONOLAYERS, PRODUCTS AND APPARATUS MADE FROM SUCH COMPOSITIONS AND MONOLAYERS, AND METHODS OF MAKING AND USING SUCH COMPOSITIONS, MONOLAYERS, PRODUCTS, AND APPARATUS - Triphosphonate compositions, self-assembled triphosphonate monolayers, products and apparatus made thereof, and methods of making and using such compositions, monolayers, products, and apparatus. | 2021-07-01 |
20210198296 | PROCESSES FOR PREPARING OLIGOMERS - Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to sealing up oligomer synthesis while maintaining overall yield and parity of a synthesized oligomer. | 2021-07-01 |
20210198297 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND - Provided are an organometallic compound, an organic light-emitting device including the same, and a diagnostic composition including the same. The organometallic compound is represented by Formula 1 | 2021-07-01 |
20210198298 | LUMINESCENT MATERIAL AND ELECTROLUMINESCENT DISPLAY DEVICE USING THE SAME - A new luminescent material and an electroluminescent display device using the same are disclosed, in which the luminescent material includes a compound expressed by the following chemical formula 1 and may be used as a dopant of a light emitting layer of a green, yellow-green or red color: | 2021-07-01 |
20210198299 | METAL ORGANIC COMPOUNDS - The invention relates to the synthesis and provision of a new class of volatile metal organic compounds based on bis(alkylimine)glyoxal and bis(dialkylhydrazone)glyoxal ligands in combination with cyclopentadienide and alkyl ligands for use in ALD and CVD processes. | 2021-07-01 |
20210198300 | TRANSITION METAL COMPOUND AND METHOD FOR PRODUCING OLEFIN POLYMER - A transition metal compound from Periodic Table Group 3 to 10 or lanthanide, of formula (I): | 2021-07-01 |
20210198302 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR REDUCING AMMONIA LEVELS - Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy). | 2021-07-01 |
20210198303 | Steviol Glycoside Compounds, Compositions For Oral Ingestion Or Use, And Method For Enhancing Steviol Glycoside Solubility - Novel steviol glycoside compounds characterized by a first group of four glucopyranose residues attached via the number 13 carbon (C13) of the steviol moiety and a second group of two or three glucopyranose residues attached via the number 19 carbon (C19) of the steviol moiety are described, and exemplified by compounds 1-4. These compounds can be present in a composition with other steviol glycosides (e.g., Reb D and Reb M) to enhance their solubilities. Accordingly, the novel compounds can facilitate the preparation of Compound name (C-13) aqueous compositions having a higher concentration of steviol glycosides. A steviol glycoside composition including one or more of compounds 1-4 can be used as a sweetener composition to sweeten other compositions (sweetenable compositions) such as foods, beverages, medicines, oral hygiene compositions, nutraceuticals, and the like. | 2021-07-01 |
20210198304 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE - The present invention relates to a synthetic saccharide of general formula (I) that is related to | 2021-07-01 |
20210198305 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF - Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown. | 2021-07-01 |
20210198306 | ANTISENSE NUCLEIC ACIDS - The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. | 2021-07-01 |
20210198307 | METHOD FOR PRODUCING ACTIVE GCMAF - The purpose of the present invention is to provide a method for producing active GcMAF more simply and at a high yield. The present invention is a method for producing active GcMAF comprising a step for culturing host cells which are transfected with a VDBP expression vector in serum-free medium. This culture is preferably a suspension culture. In addition, this method for producing active GcMAF is also characterized by not requiring an enzyme treatment step for deglycosylation. | 2021-07-01 |
20210198308 | HONEY PROTEOMICS FOR HONEYBEE DISEASE AND ENVIRONMENTAL BIOMONITORING - Methods for isolating proteins from a honey sample are provided. The methods include contacting the honey sample with a substrate functionalized with one or more reactive dyes and recovering proteins associated with the substrate. Methods for detecting proteins in a honey sample and assessing the risk of colony collapse disorder are also provided. | 2021-07-01 |
20210198309 | METHOD FOR PURIFYING ANTIBODY OR ANTIBODY-LIKE MOLECULE - The objective of the present invention is to provide a method capable of efficiently removing an impurity from an aqueous solution or a suspension comprising an antibody or an antibody-like molecule and the impurity. The method for purifying an antibody or an antibody-like molecule according to the present invention is characterized in treating an aqueous solution or a suspension comprising the antibody or the antibody-like molecule and an impurity with a water-insoluble inorganic compound, wherein the water-insoluble inorganic compound comprises one or more elements selected from magnesium, calcium and aluminum. | 2021-07-01 |
20210198310 | EXTRACTION PROCESS FROM COLOSTRUM - The present invention relates to a method for obtaining a mixture of biological factors isolated from colostrum, characterized by one or more step of filtration and concentration that allow the separation of large proteins and pathogenic microorganisms from the permeate, and to maintain the biological factors of interest in the retentate. The present invention further comprises a method for obtaining a mixture of biological factors comprising a reduced fraction of immunoglobulins or totally free of immunoglobulins, characterized by further steps of affinity chromatography and immunoaffinity. | 2021-07-01 |
20210198311 | METHOD FOR PREPARING PRECURSOR OF RECOMBINANT HUMAN INSULIN OR ANALOGUE THEREOF - Disclosed is a method for preparing a precursor of a recombinant human insulin or an analogue thereof, comprising: a. bacterial fermentation, centrifuging a fermentation broth in a continuous flow to collect a supernatant; b. filtering the supernatant in step (a) by means of a hollow fiber membrane and collecting the filtrate; and c. purifying the filtrate in the step (b) by means of a chromatography column. The method has the advantages of streamlined steps, scalability, no use of organic solvents, high yield, etc. The purity of the insulin precursor can exceed 90%, the host cell protein removal rate exceeds 90%, and the exogenous DNA removal rate is 89% or greater, achieving less than 0.1 ng/mg. | 2021-07-01 |
20210198312 | GROWTH FACTOR CONCENTRATE AND METHOD OF MANUFACTURE THEREOF - The present invention relates to a growth factor concentrate and methods of making and using the same. | 2021-07-01 |
20210198313 | METHOD OF PRODUCING IMIDAZOLE DIPEPTIDES - It is an objective of the present invention to provide a method of producing imidazole dipeptides that reduces burden and time for an elution treatment when compared to the prior arts, and furthermore, that can produce high purity imidazole dipeptides with less contamination of creatinine. The above objective is achieved by a method of producing high purity imidazole dipeptides, comprising: (1) subjecting an animal extract containing imidazole dipeptides and creatinine to an ion adsorption treatment in which the animal extract is brought into contact with a strongly acidic cation exchange resin having an alkali metal salt type of ion exchange group at a predetermined pH value to adsorb the imidazole dipeptides onto the resin; and (2) subjecting the strongly acidic cation exchange resin adsorbing the imidazole dipeptides to an elution treatment with the use of an aqueous alkaline solution and at a predetermined pH value to obtain high purity imidazole dipeptides. | 2021-07-01 |
20210198314 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY - Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: | 2021-07-01 |
20210198315 | PROCESS FOR SYNTHESIS OF PEPTIDE COMPOUNDS - Disclosed is a new process for preparing dipyrrolidine peptide compounds such as, for example, GLYX-13. Advantageously, the process may be industrially scalable and cost-effective and use less toxic reagents and/or solvents. Further, the process may be used to prepare peptide compounds having improved purity. | 2021-07-01 |
20210198316 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS - Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 2021-07-01 |
20210198317 | REACTIVE OXYGEN PRODUCTION INHIBITOR AND/OR SCAVENGING PROMOTER - The present invention provides a production inhibitor and/or scavenging promoter for reactive oxygen, and relates to a production inhibitor and/or scavenging promoter for reactive oxygen containing as an active ingredient a peptide having histidine-rich sequence. The histidine-rich sequence is the amino acid sequence identified by any one or a plurality of the following SEQ ID NOs: 2 to 8; (SEQ ID NO: 2) DLHPH; (SEQ ID NO: 3) KHHSH; (SEQ ID NO: 4) EQHPH; (SEQ ID NO: 5) GHHPH; (SEQ ID NO: 6) AHHPH; (SEQ ID NO: 7) EHDTH; and (SEQ ID NO: 8) RQHPH. | 2021-07-01 |
20210198318 | Methods and Compositions for Treating Diseases and Conditions Associated with Gonadotropin Releasing Hormone Receptor - The disclosure is directed in non-limiting embodiments to compounds, compositions, and methods of treating conditions and diseases associated with activation of the gonadotropin GnRH receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain embodiments include peptides which at least partially comprise D-amino acids, such as retro-inverso D-amino acid (RID) peptides, which are able to bind with high affinity to GnRHR AAbs. | 2021-07-01 |
20210198319 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF - The present invention provides cytotoxic peptides, analogs thereof and fragments thereof, conjugates of said peptides, analogs or fragments as well as compositions comprising same. In addition, uses of these compounds and compositions in treating cancer are provided. | 2021-07-01 |
20210198320 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF - In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products. | 2021-07-01 |
20210198321 | EPSTEIN-BARR VIRUS ANTIGEN CONSTRUCTS - The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus. | 2021-07-01 |
20210198322 | Mutant of L1 Protein of Human Papillomavirus Type 39 - The invention relates to a mutated HPV39 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV39 and HPV68, or HPV39, HPV68 and HPV70), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. | 2021-07-01 |
20210198323 | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND USES THEREOF FOR THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS DISEASE - Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a respiratory syncytial virus (“RSV”) F protein or human metapneumovirus (“hMPV”) F protein. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises (i) an RSV F protein ectodomain and NDV F protein transmembrane and cytoplasmic domains; or (ii) an hMPV F protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against RSV or hMPV as well as the prevention of RSV disease or hMPV disease. | 2021-07-01 |
20210198324 | SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES - Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided. | 2021-07-01 |
20210198325 | Programmable and Printable Biofilms as Engineered Living Materials - Three-dimensional, living, self-regenerative structures of predetermined geometry comprising solidified print material comprising a biofilm of | 2021-07-01 |
20210198326 | METHOD FOR CASCADED PROCESSING OF FRESH ALGAE - The present invention relates to a method for processing fresh algae at ambient temperature by subjecting algae to an osmotic shock and treating the disrupted algae with an enzyme composition comprising cell wall degrading enzymes. This gentle process at ambient temperature allows for the isolation of algal protein which has good solubility, also in the presence of salt and good foaming, emulsifying and water binding properties. Another advantage is that this method of protein isolation allows for cascaded biorefinery, since protein isolation may be followed by a treatment of the remaining biomass with carbohydrate degrading enzymes to produce clean biogas in high yields and a mineral rich water stream in anaerobic digestion. | 2021-07-01 |
20210198327 | SUMO AND USES THEREOF - A protein that is at least one SUMO protein, or a variant or a fragment thereof or a fusion protein including a SUMO protein is for use in the treatment of neurodegenerative and/or neurological disorders. A pharmaceutical composition includes a protein that is at least one SUMO protein or a variant or a fragment thereof or a fusion protein including a SUMO protein and pharmaceutically acceptable carriers. | 2021-07-01 |
20210198328 | MODULATED CAS-INHIBITORS - The present invention relates to a polynucleotide encoding a fusion polypeptide comprising an anti-CRISPR (Acr) polypeptide, wherein said fusion polypeptide further comprises a receptor domain changing conformation upon reception of a stimulus. The present invention also relates to a vector comprising the polynucleotide of the present invention, to a bipartite Acr polypeptide comprising a first partial Acr polypeptide comprising amino acids corresponding to amino acids 10 to 62 of SEQ ID NO: 1, and a second partial Acr polypeptide comprising amino acids corresponding to amino acids 67 to 77 of SEQ ID NO: 1, and to a host cell comprising the aforesaid polynucleotide compounds. The present invention also relates to the said compounds for use in medicine, in particular for use in treatment and/or prevention of genetic disease, neurodegenerative disease, cancer, and/or infectious disease. Moreover, the present invention also relates to a kit, methods, and uses related thereto. | 2021-07-01 |
20210198329 | PEPTIDES FOR TARGETING LRP6-OVEREXPRESSED CELLS - A composition for targeting low-density lipoprotein receptor-related protein 6 (LRP6)-overexpressed cells. The composition includes a peptide including at least one of SEQ ID NO: 1 and SEQ ID NO: 3. | 2021-07-01 |
20210198330 | BASE EDITORS AND USES THEREOF - Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. The disclosure provides fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cas9 or variants thereof, and nucleic acid editing proteins such as cytidine deaminase domains (e.g., novel cytidine deaminases generated by ancestral sequence reconstruction), and adenosine deaminases that deaminate adenine in DNA. Aspects of the disclosure relate to fusion proteins (e.g., base editors) that have improved expression and/or localize efficiently to the nucleus. In some embodiments, base editors are codon optimized for expression in mammalian cells. In some embodiments, base editors include multiple nuclear localization sequences (e.g., bipartite NLSs), e.g., at least two NLSs. In some embodiments, methods for targeted nucleic acid editing are provided. | 2021-07-01 |
20210198331 | MIC-1 COMPOUNDS AND USE THEREOF - The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds. | 2021-07-01 |
20210198332 | BIPARTITE MOLECULES AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH ABNORMAL PROTEIN AGGREGATES - Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates. | 2021-07-01 |